Author:
Marín-Sánchez Alberto,Martínez-Fernández Gonzalo,Gómez-Catalán Irene,Montoya-Morcillo Mari Carmen,Algarra-Algarra Jesús Lorenzo,Ibañez-García Ángela,Hernández-Fernández Francisco,Romero-Macías Juan Ramón
Subject
Cancer Research,Cell Biology,Genetics,Hematology,Molecular Biology
Reference30 articles.
1. Manual Práctico de Hematología Clínica;Sanz,2019
2. Ten-year follow-up after intense chemoimmunotherapy with rituximab–hyper-CVAD alternating with rituximab–high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma;Romaguera;Br J Haematol,2010
3. Hyper-CVAD and rituximab for de novo Burkitt lymphoma/leukemia;Thomas;Blood,2011
4. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia;Thomas;J Clin Oncol,2010
5. Update of the M. D. Anderson Cancer Center experience with hyper-CVAD and rituximab for the treatment of mantle cell and Burkitt-type lymphomas;Fayad;Clin Lymphoma Myeloma,2007
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献